Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Ramalingam

Showing results (311-320 of 502) with videos related to

Pageof 51
Sort By:
The Oncologist|September 19, 2025
Phase I study of palbociclib with cisplatin or carboplatin in the management of patients with advanced pancreatic cancerOlatunji B Alese, Robert Donald Harvey, Christina Wu, et al.
Clinical Lung Cancer|January 4, 2017
Pulmonary Sarcomatoid Carcinoma: An Analysis of the National Cancer Data BaseConor E Steuer, Madhusmita Behera, Yuan Liu, et al.
Clinical Lung Cancer|August 28, 2012
Survival analysis of patients with stage I non-small-cell lung cancer using clinical and DNA repair pathway expression variablesMadhusmita Behera, John J Heine, Gabriel L Sica, et al.
Cancer|September 3, 2021
JASPER: Phase 2 trial of first-line niraparib plus pembrolizumab in patients with advanced non-small cell lung cancerSuresh S Ramalingam, Eddie Thara, Mark M Awad, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 27, 2017
Phase II randomized trial of carboplatin, paclitaxel, bevacizumab with or without cixutumumab (IMC-A12) in patients with advanced non-squamous, non-small-cell lung cancer: a trial of the ECOG-ACRIN Cancer Research Group (E3508)A Argiris, J W Lee, J Stevenson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2017
Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 DegradationPuyu Shi, You-Take Oh, Liang Deng, et al.
Clinical Lung Cancer|April 15, 2018
Update on International Cooperative Groups Studies in Thoracic Malignancies: The Emergence of ImmunotherapyNavika D Shukla, Ameen A Salahudeen, Gregory A Taylor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 15, 2010
Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group studySuresh S Ramalingam, Shivaani Kummar, John Sarantopoulos, et al.
The Journal of Clinical Investigation|December 12, 2017
Targeting Mcl-1 enhances DNA replication stress sensitivity to cancer therapyGuo Chen, Andrew T Magis, Ke Xu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 27, 2015
Impact of an Interactive On-line Tool on Therapeutic Decision-Making for Patients with Advanced Non-Small-Cell Lung CancerHelen Chow, Martin J Edelman, Giuiseppe Giaccone, et al.
Pageof 51

Showing results (311-320 of 502) with videos related to

Sort By:
Pageof 51
The Oncologist|September 19, 2025
Phase I study of palbociclib with cisplatin or carboplatin in the management of patients with advanced pancreatic cancerOlatunji B Alese, Robert Donald Harvey, Christina Wu, et al.
Clinical Lung Cancer|January 4, 2017
Pulmonary Sarcomatoid Carcinoma: An Analysis of the National Cancer Data BaseConor E Steuer, Madhusmita Behera, Yuan Liu, et al.
Clinical Lung Cancer|August 28, 2012
Survival analysis of patients with stage I non-small-cell lung cancer using clinical and DNA repair pathway expression variablesMadhusmita Behera, John J Heine, Gabriel L Sica, et al.
Cancer|September 3, 2021
JASPER: Phase 2 trial of first-line niraparib plus pembrolizumab in patients with advanced non-small cell lung cancerSuresh S Ramalingam, Eddie Thara, Mark M Awad, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 27, 2017
Phase II randomized trial of carboplatin, paclitaxel, bevacizumab with or without cixutumumab (IMC-A12) in patients with advanced non-squamous, non-small-cell lung cancer: a trial of the ECOG-ACRIN Cancer Research Group (E3508)A Argiris, J W Lee, J Stevenson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2017
Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 DegradationPuyu Shi, You-Take Oh, Liang Deng, et al.
Clinical Lung Cancer|April 15, 2018
Update on International Cooperative Groups Studies in Thoracic Malignancies: The Emergence of ImmunotherapyNavika D Shukla, Ameen A Salahudeen, Gregory A Taylor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 15, 2010
Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group studySuresh S Ramalingam, Shivaani Kummar, John Sarantopoulos, et al.
The Journal of Clinical Investigation|December 12, 2017
Targeting Mcl-1 enhances DNA replication stress sensitivity to cancer therapyGuo Chen, Andrew T Magis, Ke Xu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 27, 2015
Impact of an Interactive On-line Tool on Therapeutic Decision-Making for Patients with Advanced Non-Small-Cell Lung CancerHelen Chow, Martin J Edelman, Giuiseppe Giaccone, et al.
Pageof 51